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Abstract 
Chlamydia trachomatis infections encountered during pregnancy can lead to many complications 
for both mother and neonate if left untreated. A systematic review and a meta-analysis were 
conducted to analyse the efficacy of antibiotic treatment infection during pregnancy that 
established the most effective antibiotic to treat Chlamydia trachomatis infections during 
pregnancy. PubMed and Cochrane Library were searched to the end of 2019. Randomised 
control trials that aligned with inclusion criteria of relevant antibiotics Azithromycin, 
Erythromycin, Clindamycin and Amoxicillin during Pregnancy was included. A systematic 
review and meta-analysis were used to calculate pooled (i) success of treatment for each 
antibiotic in several trials and (ii) the total adverse side effects for each drug encountered in 
several trials. Randomised controlled trials (RCTs) selected included 1917 pregnant patients with 
Chlamydia infections, and 851 have completed follow up assessments. Data from three RCTs 
observed a higher success of treatment for Azithromycin versus Erythromycin, fixed effect 
model, odds ratio (OR) = 0.67, 95% confidence interval (CI), 0.32-1.80. Data from three RCTs 
observed a higher success of treatment for Clindamycin versus Erythromycin OR = 2.43 95%, 
CI:2.00-2.60. Data from two RCTs showed a higher success of treatment for Amoxicillin versus 
Erythromycin OR = 3.74, 95%, CI:0.68-13.66. Analysis established that Erythromycin resulted 
in the most adverse side effects. Azithromycin was determined as the most effective antibiotic to 
treat C. trachomatis infections during pregnancy due to the high success of treatment. 
Clindamycin is capable of eradicating C. trachomatis infections in pregnancy and can be 
considered a secondary antibiotic treatment with fewer incidences of adverse side effects and 
high levels of successful treatment of the infection, however, due to a lack of studies more 
analysis will be required to confirm the efficacy of Clindamycin. 
Keywords: a meta-analysis, systematic review, Randomized Controlled Trials Chlamydia 
trachomatis, Sexually Transmitted Diseases (STD), pregnancy infections, the efficacy of 
antibiotics, Antibiotic dosage, bacteriostatic effect. 
1. Introduction 
1.1 Chlamydia trachomatis infections  
The Gram-negative intracellular bacterium Chlamydia trachomatis is the causative agent of one 
of the most common sexually transmitted disease (STD), Chlamydia (Mohammadzadeh et al., 
2019). Studies in the UK showed that on average of 2-26% of pregnant women are found to be 
positive for Chlamydia during Pregnancy (Cluver et al., 2017). Prevalence of C. trachomatis 
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infections can be attributed to its predominantly calm nature, as infections are largely 
asymptomatic. The infection, however, in women, can clinically present as mucopurulent 
cervicitis, urethritis and endometritis. Chlamydia is believed to be the leading cause worldwide 
of Pelvic Inflammatory Disease (PID) and infertility with links to ectopic pregnancy, miscarriage 
and premature rupture of membranes (Brocklehurst and Rooney, 1998). C. trachomatis 
infections encountered during pregnancy are usually asymptomatic. However, if left untreated, it 
can result in spontaneous miscarriage in the first trimester, preterm labour and premature 
aminorexes, giving rise to premature neonates. Untreated Chlamydia infections leave the neonate 
exposed to an increased chance of obtaining an infection post-natal, usually presenting itself as 
ophthalmia neonatorum or pneumonitis (Allaire, Nathan and Martens, 1995).  Treatment for 
Chlamydia is a simple procedure with the prescription of a seven-day course of Doxycycline or a 
single dose of Azithromycin. Conversely, the exact or primary application of one particular 
antibiotic to treat C. trachomatis infections in pregnancy, safe for both mother and neonate is 
something still somewhat unclear in medical practice. The World Health Organisation (WHO) 
guidelines have described therapeutic options for the treatment of Chlamydia during Pregnancy 
as poor to moderate. WHO recommends that there is an increased need for more Randomised 
Control trials (RCTs) to compare treatments, dosage, and gestational time frames, on eradicating 
this such infection (WHO Guidelines for the management of sexually transmitted infections, 
2001). Administering antibiotics during pregnancy has to consider both the health of the mother 
as well as the neonate. The use of antibiotics during pregnancy changes the micro-biotic 
environment of the birth canal, which is where a neonate obtains its microbiome from during 
vaginal delivery. This mechanism is vitally important in the developing immune system of a 
neonate (Kuperman and Koren, 2016). 
1.2 Antibiotic treatment for STD during Pregnancy 
Antibiotics deemed unsafe to use during pregnancy by the WHO include Doxycycline, 
Tetracycline and Ofloxacin. Tetracycline and (Doxycycline) are ordinarily used to treat non-
pregnant patients with diagnosed Chlamydial infections. Tetracycline antibiotics bind to 
pathogenic ribosomes preventing the attachment of the aminoacyl tRNA to the RNA-ribosome 
complex, inhibiting further biosynthesis of proteins, thus eradicating the presence of a bacterial 
infection (Batagol, 1980). 
Tetracyclines, however, have a special affinity for metal cations, especially calcium. This affinity 
to calcium has led to the consensus of it being unsafe to use Tetracycline antibiotics to treat 
Chlamydia post the first trimester of pregnancy. These antibiotics are attributed to negative 
implications on foetal teeth, enamel hypoplasia and bone development of a foetus. The use of 
Tetracyclines altogether during any stage of pregnancy and the developmental years of a child is 
no longer medically advisable nor acceptable unless necessary. Another family of drugs 
ordinarily used to treat C. trachomatis infections: Fluoroquinolones such as Ofloxacin which are 
especially well suited for the treatment of C. trachomatis cervical infections in non-pregnant 
patients but is yet another drug deemed unsafe to use in Pregnancy (Faro et al., 1991). 
Fluoroquinolones are only to be administered during pregnancy when the benefit for the mother 
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outweighs the possible risk to the foetus due to its detrimental effects on foetal cartilage 
formation and bone development.  
There have been progressively more studies regarding multidrug-resistant strains of C. 
trachomatis bacteria. Antibiotic resistance raises more complications of an infection encountered 
during pregnancy, with further limitations and restrictions to types of antibiotics that are safe to 
use. In recent studies, some Chlamydial infections have been noted to show resistance to the 
antibiotics: Azithromycin. The resistance to Azithromycin has been attributed to mutations in the 
peptidyl transferase region of 23S rRNA genes of the Chlamydia trachomatis bacterium (Figure 
1), and these genes prevent the drug from inhibiting the translation of mRNA in the bacteria, 
enabling the infection to persist (Zhu et al., 2010). 
  
  
 
 
 
 
 
 
 
Figure 1. The peptidyl transferase region of 23S rRNA genes of the C. trachomatis bacteria 
attributed to the resistance to Azithromycin. 
The side effects can result in the infection persisting due to insufficient exposure of the bacteria 
to the administered antibiotic. The pregnancy symptoms such as morning sickness (hyperemesis 
gravidarum), fatigue and headaches have to be taken into consideration when it comes to what is 
classed as an adverse side effect encountered as a result of a drug, versus a symptom of 
pregnancy itself. Changes encountered during pregnancy include increased blood volume; 
therefore an increased glomerular filtration rate altering length of the drug stays in circulation 
and the efficacy of a drug itself to relay its bacteriostatic or bacteriolytic function (Sarkar, 
Woodland C, Koren and Einarson, 2006). Considerations need to be made to the changes 
encountered as a part of normal pregnancy and adjustments in the pharmacokinetics of a drug 
may need to be calculated to sufficiently inhibit bacterial infections such as Chlamydia in 
Pregnancy. Similar to issues with the timing of the application of Tetracycline antibiotics (post 
the first trimester of pregnancy), considerations could be made towards the most inoffensive 
trimester to administer each different drug. Alongside the side effects encountered during 
different trimesters of pregnancy could alter the efficacy of each drug. 
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Figure 2. Chemical structures of the selected antibiotics. Relative molecular formula and the 
structural similarities between of the selected drugs Azithromycin and Erythromycin, and 
Clindamycin and Amoxicillin during Pregnancy. 
All drugs involved in this study are classed as category B pregnancy drugs, and their applications 
are considered safe to both mother and neonate during pregnancy depicted in Figure 2. 
Azithromycin and Erythromycin consist of the same elements Carbon, Hydrogen, Nitrogen and 
Oxygen within different overall structures. Furthermore, despite Clindamycin and Amoxicillin 
not belonging to the same class of antibiotics (like the macrolides Azithromycin and 
Erythromycin), they consist of the same elements Carbon, Hydrogen, Nitrogen, Oxygen and 
Sulphur with different structural compositions. 
1.3 Azithromycin 
The azalide Azithromycin is a derivative of the more broad-spectrum macrolide Erythromycin. 
Azithromycin effects by binding and inhibiting peptidyl transferase activity interfering with 
amino acid translocation during the process of translation bacteria (Engel, 1992). Azithromycin's 
mechanism of action is not directly toxic to chlamydial elementary bodies but does inhibit the 
bacterial protein synthesis in chlamydia-infected cells. Its inhibition is characteristically quite 
rapid and only requires brief exposure to exhibit its effects. Studies suggest that Azithromycin 
does have a higher failure rate than Doxycycline, which is ordinarily used to treat C. trachomatis 
infections in non-pregnant patients (Sarkar, Woodland C, Koren and Einarson, 2006).  
1.4 Erythromycin 
Erythromycin is a more broad-spectrum macrolide antibiotic that diffuses through the bacterial 
cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome, relaying its 
bacteriostatic effects on the infection. Studies suggest the specific gastrointestinal issues 
associated with the antibiotic Erythromycin are likely due to an increased risk of pyloric stenosis 
(narrowing of the opening from the stomach to the small intestines), (Mourad, Sweet, Sugg and 
Schachter, 1980). Erythromycin's characteristic of undesirable gastrointestinal side effects, it is 
likely to impede on the efficacy of the drug itself, limiting the drugs exposure to the bacteria. 
1.5 Clindamycin 
The lincosamide antibiotic Clindamycin acts on Chlamydial trachomatis infections by binding to 
bacterial 50S ribosomal subunits. It exhibits a bacteriostatic effect, and as it binds to ribosomal 
sub-units, it has a prolonged post-antibiotic effect (CAMPBELL and DODSON, 1990). 
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Clindamycin is less notably used to treat Chlamydial infections but is considered a valuable drug 
for patients that have certain allergies or intolerances to antibiotics (Erythromycin). It is likely to 
be effective at inhibiting C. trachomatis infections, but issues of compliance may affect the total 
success of treatment (Turrentine, Troyer and Gonik, 1995). A rash is also attributed to 
intolerance of Clindamycin which could alter patient compliance and success of treatment 
(Gilbert, 1992). 
1.6 Amoxicillin 
This penicillin derivative antibiotic inhibits the multiplication of reticulate bodies and the 
differentiation of reticulate bodies into infectious elementary bodies, without necessarily exerting 
a lethal effect on the organism (Alary et al., 1994). This allows for the subclinical progression of 
latent Chlamydial infections to persist. Such infections can be detected by molecular diagnosis 
methods such as Real-Time Polymerase Chain Reaction to determine the presence of any 
bacterial genetic remanence active or latent that may retain within a patient. Amoxicillin's mode 
of action suggests it's likely to be somewhat of a weak agent against C. trachomatis bacteria. 
Amoxicillin is also attributed to an increased need for routine monitoring, exacerbating medical 
expenses and time (Jacobson et al., 2001). However, notable adverse side effects are not 
attributed to Amoxicillin application and efficacy of the therapy. 
 1.7 Study objectives 
This study elucidates to establish the antibiotic with minimal adverse side effects to both mother 
and neonate but maximum inhibitory effects on the Chlamydial trachomatis infections during 
pregnancy. Azithromycin, Erythromycin, Clindamycin (macrolide), and Amoxicillin (ß-lactam) 
antibiotics are considered as they are routinely used in Chlamydial trachomatis infections. The 
side effects encountered by the mother and neonate for each selected antibiotic was evaluated to 
help determine the most employable primary drug to administer to a pregnant mother with a C. 
trachomatis infection.  
2. Method 
2.1 Study design, information sources and search strategy. 
This systematic review and meta-analysis follow the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines (Shamseer, L., et al 2015). The electronic 
database PubMed was used to extract the studies. As the study method was a systematic review 
and a Meta-analysis, and not included any patient sensitive/identifiable data, ethical 
consideration was not considered. 
2.2 Inclusion criteria 
RCT prioritizing the use of the antibiotics; Azithromycin, Erythromycin, Clindamycin, 
Amoxicillin or placebo used any time antenatally to treat a Chlamydial infection were included. 
All articles published from 1980- 2019 were selected. Keywords such as 'C. trachomatis', 
'pregnancy', 'treatment', 'Azithromycin', 'Erythromycin', 'Clindamycin', 'Amoxicillin', 'neonate'. 
RCTs of pregnant women who tested positive for asymptomatic/symptomatic Chlamydia during 
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any trimester of pregnancy were considered. Moreover, other comorbidities such as other 
sexually transmitted infections alongside a Chlamydial infection also included. Only articles 
reported in the English language were included. 
2.3 Exclusion criteria 
Studies conducted by case reports, comments, listed opinions, narrative reviews and studies 
using non-standardised genital testing that did not meet the inclusion criteria were excluded. 
Also, studies published other than the English language were excluded from this study. 
2.4 Quality assessment and data collection.  
Eligible studies were selected based on the considering adequate sample size, clarity of research 
aims, appropriateness of design, recruitment, data collection, analysis and reporting of the study 
findings. Full text of the eligible studies assessed against the inclusion criteria. 
2.5 Outcome of interest 
The primary outcome was focused on the comparison of the efficacy of each selected antibiotic 
on eradicating the Chlamydia infection. In a secondary analysis, focused on comparing the safety 
of the antibiotic and its side effects upon the mother and the neonate.  
2.6 Statistical analysis 
The study analysed the pooled prevalence of on Treatment failure of each antibiotic, and 
comparison of the total amount of side effects encountered by each antibiotic for Chlamydia 
infection using Review Manager (RevMan) software version 5. A forest plot was analysed using 
Meta-analysis. The extracted data were analysed, and the results were reported using a random-
effects model (Der Simonian R et al., 1986) with 95% confidence interval (CI). 
2.7 Study selection 
After the evaluation of exclusion/inclusion criteria and the quality of articles, 7 eligible studies, 
were included in the meta-analysis (Figure 3). 
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The studies excluded based on not 
being RCT’s or incompatible in the 
details of their title or abstract for this 
study. 
• Being a review, not an RCT. n=3  
• Chlamydia trachomatis infections 
not being encountered during 
pregnancy (in the general 
population).n=9 
• Chlamydia trachomatis infections 
linked to abortion, ectopic pregnancy 
or miscarriage. n=11 
• Postnatal chlamydia infection 
treatment. n=3 
• Neonatal chlamydial infection 
treatment. n=5 
• Effect of chlamydial infections on 
fertility. n=3 
• Non-specific to chlamydial 
infections in pregnancy (generalised 
sexually transmitted infections). n=9 
• Quantitative screening/ diagnosis 
of Chlamydia trachomatis infection not 
including treatments. n=7 
• Different drug treatment for C. 
trachomatis infection. n=5 
• Generally irrelevant to the subject 
of this study. n=26 
Excluded n = 81 
 
Studies identified through database 
searching 
n = 92 
 
Records were removed as a result of 
Irrelevant, non RCT and duplicates n = 81 
Relevant RCTs selected n=11 
Removed RCT due to no abstract or 
untraceable  n= 4 
Studies included in quantitative 
synthesis (meta-analysis) 
(n = 7) 
 
 
Figure 3. Flow diagram of the reviewed articles establishing the randomised control trials 
(RCTs) to be used in the meta-analysis. 
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3. Results 
Table 1: Characteristics of the seven RCTs involved in the meta-analysis 
Reference and year of 
publication 
Drug 
Dosage and 
treatment period 
Gestational age of 
the patient (mean 
weeks) 
Number of 
enrolled 
patients 
Number of 
clinically 
evaluated 
patients 
Percentage 
success of 
treatment 
Percentage 
failure of 
treatment 
Alary et al., 1994 
Amoxicillin  
500mg x3 a day, 7 
days  
17.3 105 
100 
99/100  1/100 
99.00% 1% 
Erythromycin 
500mg x4 a day, 7 
days 
16.9 105 99 
87/99  Dec-99 
87.90% 12.10% 
Edwards et al., 1996 
Azithromycin 1g single dose 20.4 65 62 
58/62  Apr-62 
93.50% 6.50% 
Erythromycin 
500mg x4 a day, 7 
days 
28.6 65 64 
46/64  Aug-64 
71.90% 12.50% 
Rosenn, Macones and 
Silverman, 1995 
Azithromycin 1g single dose 19.3+-4.5 24 23 
21/23  23-Feb 
91.30% 8.70% 
Erythromycin 
500mg x4 a day, 7 
days 
19.5 +-3.5 24 22 
17/22  22-May 
77.30% 22.70% 
Turrentine, Troyer and 
Gonik, 1995 
Amoxicillin 
500mg x3 a day, 7 
days  
24.9+-6.3 57 55 
52/55  Mar-55 
94.00% 5.50% 
Erythromycin 
500mg x4 a day, 7 
days 
24.3+-6.6 56 53 
51/53  Feb-53 
96.00% 3.80% 
Clindamycin 
600mg x3 a day, 10 
days 
       22.9+-6.2                                                                55 52 
51/52  Jan-52 
98.00% 1.90% 
 
Jacobson et al., 2001 
Azithromycin 1g single dose                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     20.6+-8.8 63 55
35/55  20/55 
63.60% 36.40% 
Amoxicillin 
500mg x3 a day, 
7 days 
21.3+-9.2 66 55 
32/55 23/55 
58.20% 41.80% 
Adair, 1998 
Azithromycin 
1g dissolved in 
60ml of water, 
single dose 
N/A (similar 
gestational age) 
53 42 
37/42  May-42 
88.10% 11.90% 
Erythromycin 
500mg x4 a day, 
7 days 
N/A (similar 
gestational age) 
53 43 
40/43 Mar-43 
93.00% 7.00% 
Gilbert, 1992 
Clindamycin 
450mg x4 a day, 
14 days 
20 42 42 
39/42  Mar-42 
93.00% 7.10% 
Erythromycin 
333mg x4 a day, 
14 days 
20 42 42 
35/42  Jul-42 
84.00% 16.70% 
Placebo  N/A 20 42 42 
0/42 42/42 
0.00% 100% 
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3.1 Analysis of RCT characteristics. 
Table 1 describes the characteristics of seven RCT's included in the meta-analysis of this study. 
In all seven RCTs, there was very little differentiation in demographic factors such as the number 
of sexual partners, gestational age (excluding Edwards et al., 1996). In two RCT's the treatment 
of both pregnant mother and their consistent sexual partner was mentioned with the 
contraceptive protective methods also being advised. However, in one study it was insinuated 
that the sexual partners of two of the patients were not treated for the Chlamydia and did not 
follow the advice of having protected sex for the duration of the study. As a result, the two 
patients in the study showed a positive reading for the C. trachomatis infection after completion 
of the course of antibiotic treatment during the trial likely due to reinfection. 
In three RCTs, Azithromycin was administered as a single 1g powdered tablet dose, in one RCT 
(Adair, 1998) it was given as a single 1g dose dissolved in 60ml of water to the patients. Five 
RCTs applied the same dose and treatment period for Erythromycin of 500mg, four times a day, 
for seven days, with one RCT (Gilbert, 1992) administering 333mg, four times a day, for 
fourteen days. Clindamycin was administered at different doses for different lengths of time, in 
one RCT (Turrentine, Troyer and Gonik 1995) the dose and treatment period was 600mg, three 
times a day, for ten days; in another RCT (Gilbert 1992) Clindamycin was administered at 
450mg, four times a day for fourteen days. Amoxicillin was consistently administered at 500mg 
four times a day, for seven days in all three RCTs. 
3.2 Azithromycin versus Erythromycin treatment failure 
 
 
 
 
Figure 4. Forest Plot showing treatment failure of Azithromycin compared to Erythromycin in 
clinically evaluated patients. 
As represented in Figure 5, Azithromycin compared with Erythromycin in two RCTs (Edwards 
et al, 1996 and Rosenn, Macones and Silverman, 1995) showed fewer incidences of treatment 
failure for Azithromycin. 256 clinically evaluated (CE) patients, fixed effect model, odds ratio 
(OR) = 0.67, 95% confidence interval (CI), 0.32-1.80, data from three RCTs). However, one 
RCT (Adair, 1998) showed to support Erythromycin over Azithromycin with a higher rate of 
treatment failure regarding Azithromycin in that one RCT. 
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3.3 Clindamycin versus Erythromycin treatment failure 
 
 
 
 
 
 
Figure 5. Forest Plot showing treatment failure of Erythromycin compared to Clindamycin in 
clinically evaluated patients. 
The treatment failure of Erythromycin was considerably higher than what was encountered in the 
trials of Clindamycin in clinically evaluated patients of both RCTs (Gilbert, 1992 and Turrentine, 
Troyer and Gonik, 1995), with 189 clinically evaluated patients, fixed effect model, odds ratio 
(OR) = 2.43 95% confidence interval (CI), 2.00-2.60, data from two RCTs. 
3.4 Amoxicillin versus Erythromycin treatment failure 
 
 
 
 
 
 
Figure 6. Forest plot showing treatment failure of Erythromycin compared to Amoxicillin in 
clinically evaluated patients. 
The two RCTs compared in the forest plot diagram do not corroborate that same account. One 
RCT (Alary et al,1994) appears to show a higher affiliation to Amoxicillin describing a higher 
rate of failure concerning Erythromycin in this trial. However, in the other RCT (Turrentine, 
Troyer and Gonik, 1995) it describes a higher rate of failure of treatment concerning Amoxicillin 
with the forest plot appearing to have a higher affiliation towards and a closers position to 
Erythromycin. 307 clinically evaluated patients, fixed effect model, odds ratio (OR) = 3.74, 95% 
confidence interval (CI), 0.68-13.66, data from two RCTs). 
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3.5 Treatment failure of each drug from the RCTs  
 
 
 
 
 
 
Figure 7. The overall treatment failure encountered for each antibiotic. In blue, all seven RCTs 
were included regarding the total percentages of treatment failure. In orange, the RCT of 
Jacobson et al., 2001 was excluded from the overall percentage treatment failure. 
Treatment success was described as a negative test for Chlamydia at the end of the trial in all 
seven RCTs included in the meta-analysis. Treatment failure was determined by all studies as a 
positive test result for C. trachomatis at the end of the trial or failure to complete the trial itself 
and the subsequent absence of follow up information. The RCT Jacobson et al., 2001 treatment 
failure was treated as an anomaly within this study, due to the abnormally large treatment failure 
encountered that was inconsistent to the results of the relative drugs (Azithromycin and 
Amoxicillin) involved in other RCTs. 
Table 2: Adverse side effects encountered by each antibiotic, including the total number of side 
effects encountered across all RCTs. 
Antibiotic 
used to treat 
C. trachomatis 
infection in 
RCT. 
Reference and year 
of publication 
Percentage of reported 
gastrointestinal issues 
(nausea, diarrhoea, 
abdominal pain) or rash 
during the trial. 
Total number and relative 
overall percentage of the 
side effects encountered for 
each drug from the 
respective RCTs. 
Azithromycin 
Edwards et al., 1996 12/62 (17.7%) 
28/181 (15.5%) 
Rosenn, Macones 
and Silverman, 1995 
4/22 (18.2%) 
Jacobson et al., 
2001 
6/55 (10.9%) 
Adair, 1998 6/53 (11.3%) 
Erythromycin Alary et al., 1994 32/99 (31.3%) 139/333 (41.7%) 
                       International Journal of Medical Science and Health Research 
Vol. 4, No. 04; 2020 
ISSN: 2581-3366 
www.ijmshr.com Page 88 
 
Edwards et al., 1996 42/64 (65.6%) 
Rosenn, Macones 
and Silverman, 1995 
10/22 (45.5%) 
Turrentine, Troyer 
and Gonik, 1995 
14/53 (24.5%) 
Adair, 1998 
31/53 
-58.50% 
Gilberts, 1992 10/42 (23.8%) 
        
Clindamycin 
Turrentine, Troyer 
and Gonik, 1995 
7/52 (9.6%) 
11/94 (11.7%) 
Gilbert, 1992 4/42 (9.5%) 
Amoxicillin 
Alary et al., 1994 6/100 (6.0%) 
12/210 (5.7%) 
Turrentine, Troyer 
and Gonik, 1995 
3/55 (5.5%) 
Jacobson et al., 
2001 
3/55 (5.5%) 
 
According to Table 2, four RCTs concerning Azithromycin a total of 28 out of 181 (15.5%) of 
the patients displayed intolerance to the drugs including gastrointestinal issues (including nausea, 
diarrhoea, abdominal pain) and one patient exhibited signs of a rash. In the four RCTs 
concerning Erythromycin 139 out of 333(41.2%) of patients displayed gastrointestinal issues or a 
rash. In the two RCTs regarding Clindamycin 11 out of 94 (11.7%) patients involved 
encountered intolerance to the drug.  In the three RCTs concerning Amoxicillin a total of 12 out 
of 210 patients (5.7%), displayed gastrointestinal issues. However, there were no reports of a 
rash encountered by any of the patients in the RCTs concerning Amoxicillin. 
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3.6 Azithromycin versus Erythromycin adverse side effects 
 
 
 
 
 
 
Figure 8. Forest plot comparing the total adverse side effects encountered by patients 
administered with Azithromycin and Erythromycin. 
According to Figure 8, there is a much higher occurrence of adverse side effects in patients 
administered Erythromycin comparative to Azithromycin. In two of the RCTs (Edwards et al., 
1996 and Rosenn, Marcones and Silverman, 1995) adverse side effects referred to patients that 
had been clinically evaluated whilst one RCT (Adair, 1998) adverse side effects referred to the 
total number of patients the trial had initially intended to treat. (172 CE patients, 106 patients that 
were deemed intended to treat, fixed effect model, odds ratio (OR) =0.13, 95% confidence 
interval (CI), 0.09-0.27, data from three RCTs). 
3.7 Clindamycin versus Erythromycin adverse side effects 
 
 
 
 
Figure 9. Forest plot comparing the total adverse side effects encountered by patients 
administered Erythromycin and Clindamycin. 
According to Figure 9, the total number of adverse side effects encountered in Patients 
prescribed Erythromycin (24) is more than double comparatively when compared to 
Clindamycin (11). The forest plot displays a higher affiliation positioned towards Clindamycin 
where fewer side effects were encountered.  Both RCTs totals referred to patients that had been 
clinically evaluated, (189 CE patients, fixed effect model, odds ratio (OR) = 2.55, 95% 
confidence interval (CI), 2.31-2.97, data from two RCTs). 
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3.8 Amoxicillin versus Erythromycin adverse side effects 
 
 
 
 
Figure 10.  Forest plot comparing the total adverse side effects encountered by patients 
administered Erythromycin and Amoxicillin. 
As depicted in Figure 10, there is a higher affiliation towards Amoxicillin compared to that of 
Erythromycin. Erythromycin had 46 accounts of adverse side effects encountered in two RCTs 
compared to 9 accounts of side effects from patients administered Amoxicillin. Both RCTs 
referred to patients that had been clinically evaluated, (307 CE patients, fixed effect model, odds 
ratio (OR) = 7.04, 95% confidence interval (CI), 6.22-7.48, data from two RCTs). 
3.9 Comparison of the total amount of side effects encountered by each drug in RCTs  
 
 
 
 
 
 
 
 
 
Figure 11. Total percentage of side effects encountered for each antibiotic treatment used to treat 
C. trachomatis infections during pregnancy from the seven RCTs used in this study. 
Figure 11 shows the total percentage of adverse side effects encountered by patients for each 
drug. The most side effects encountered was regarding Erythromycin (41.7%), followed by 
Azithromycin (15.5%), Clindamycin (11.7%), and Amoxicillin with the lowest amount of side 
effects encountered (5.7%).   
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3.10 Azithromycin versus Clindamycin 
Despite RCTs being non-comparable for a meta-analysis, from Figure 11 there was a higher total 
percentage incidence of adverse side effects encountered in the four RCTs (15.5%) concerning 
Azithromycin compared to the two RCTs of Clindamycin (11.7%). 
 
3.11 Azithromycin versus Amoxicillin 
Figure 11 shows that Beta-lactam antibiotic Amoxicillin had the lowest percentage total 
incidences of adverse side effects of all antibiotics evaluated in this study (5.7%). Compared to 
that of Azithromycin (15.5%) from its four RCTs, Amoxicillin had less than half the total 
percentage incidences of recorded side effects. 
 
3.12 Clindamycin versus Amoxicillin 
Both Clindamycin and Amoxicillin had the lowest total percentage of adverse side effects 
recorded during their respective RCTs. However, in Figure 11 its shows that Clindamycin had 
more than double the percentage of adverse side effects encountered in the two RCTs concerning 
the drug (11.7%), compared to Amoxicillin (5.7%) from its three RCTs.   
 
4. Discussion 
The results from the meta-analysis and total condensed data of all RCTs (Figure 7) evaluating 
treatment success of eradicating C. trachomatis infections in pregnancy, suggested that the 
therapy of Erythromycin was the least efficacious antibiotic treatment evaluated in this study. 
Erythromycin's predicted characteristic undesirable gastrointestinal side effects led to 
understandable high levels of non-compliant patients in RCTs which significantly related to 
treatment failure. Gastrointestinal side effects encountered as a result of Erythromycin are 
thought to be caused by interactions of the drug with motilin receptors, inducing strong gastric 
and pyloric contractions and subsequent side effects characteristic to the macrolide. 
The azalide derivative of Erythromycin; Azithromycin proved somewhat more successful at 
eliminating the Chlamydial infection. Only 3 RCTs that fitted the inclusion criteria were 
comparable through a meta-analysis where two RCTs confirmed Azithromycin to have a higher 
success rate compared to Erythromycin (Edwards et al., 1996 and Rosenn, Macones and 
Silverman, 1995). One RCT however (Adair 1998) had a different method of application of 
Azithromycin compared to all other RCTs, where a single dose 1g of Azithromycin administered 
was dissolved in 60ml of water, this method seemingly decreased the efficacy of the drug. 
Azithromycin overall had a higher success rate of eradicating a C. trachomatis infection in 
pregnancy (from 88.1%-93.5%) compared to that of Erythromycin (71.9%-93.0%). Despite the 
azalide Azithromycin being a derivative of Erythromycin and having similarities chemically and 
somewhat structurally (Figure 2), there were noted differences in the two drugs evaluated in the 
results. Gastrointestinal side effects and resultant noncompliance were significantly related to 
treatment failure with Erythromycin (Edwards et al., 1996). Lack of compliance of patients in the 
RCTs of each drug can be considered a contributing factor to the decreased success rates in the 
trials involved in the comparison of these two macrolides. Erythromycin's links to pyloric 
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stenosis and subsequent gastrointestinal issues understandably led to a reduction in the patients 
involved in RCTs. (Sarkar, Woodland C, Koren and Einarson, 2006). 
Despite the low compliance rate of Erythromycin, the success of treatment and cure rates were 
relatively high. Which may suggest a shorter exposure to the drug may exert the desired effects 
on the infection but limit the adverse gastrointestinal side effects encountered. (Jelić and 
Antolović, 2016) The differences chemically between the two macrolides is Azithromycin 
consists of a lactone ring which gives it its unique pharmacokinetic profile, and this difference 
structurally can be considered to contribute to fewer incidences of gastrointestinal issues. 
(Allaire, Nathan and Martens, 1995). 
Clindamycin had a slightly higher success rate at eradicating C. trachomatis infections in 
pregnancy (93-98%) compared to Erythromycin (84%-96%). Again, this was likely linked to the 
reduced compliance encountered in RCTs by patients administered Erythromycin and 
experiencing adverse gastrointestinal side effects. In the meta-analysis of these two drugs, it was 
limited to the evaluation of only two RCTs, due to the lack of trials completed regarding 
Clindamycin and Chlamydial infections during pregnancy. Clindamycin's mode of action 
enabled a post-antibiotic effect due to its method of binding to bacterial ribosomal subunits and 
is, therefore, more likely to prevent persistent infections. Alongside this, there were few adverse 
side effects attributed to this antibiotic. However, more RCT's would be required to help 
strengthen the reliability of these findings. 
Amoxicillin appears to have the highest percentage treatment success and the lowest incidences 
of adverse side effects encountered during the RCTs. The meta-analysis for the success of 
treatment resulted in conflicting results which is similar to the opinions of varying articles 
regarding the use of Amoxicillin to treat C. trachomatis infections (especially in vitro). 
Amoxicillin had the lowest incidences of adverse side effects compared to Erythromycin in the 
meta-analysis attributed to its mode of action. Secondary to this, the mode of action of 
Amoxicillin resulted in an increased likelihood of reinfection with the presence of latent C. 
trachomatis genetic material likely to remain within the patient (detectable by RT-PCR). In 
pregnancy, the risk of reinfection by using this antibiotic would be too high with consequences 
not just for the mother but for the developing foetus and eventual neonate too. 
The detrimental capabilities of C. trachomatis infections to both pregnant mothers, foetus and 
subsequent neonate make eradicating such infections a priority in pregnancy. Due to a lack of 
RCT's performed on pregnant women with such infections, there is not a defined consensus of 
the exact application of one specific antibiotic (Rahangdale et al., 2006). Difficulties arose when 
comparing the efficacy of each antibiotic against each other due to a shortage of RCT's to 
facilitate the research. 
5. Limitations of the study 
There were very few studies regarding the use of Amoxicillin to treat such infections during 
pregnancy and even fewer for the lincosamide Clindamycin. Weaknesses encountered during the 
research included the lack of comparative RCTs for each drug compared in this study, with 
comparative RCTs largely focused on the comparison of Azithromycin and Erythromycin there 
were noticeable limitations surrounding the drugs Clindamycin and Amoxicillin to align with all 
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of the inclusion criteria of this study. To improve upon this, alike what the WHO suggested, 
further research and RCTs of antibiotics applied in pregnancy need to be made. For the obvious 
ethical reason there lie some restrictions attaining willing participants to partake in such trials 
during pregnancy with risks not only to themselves but to the foetus too. 
The treatment failure encountered during the RCTs evaluated in this study could also be 
attributed to incorrect drug uptake by patients, reinfection of C. trachomatis by an untreated 
partner, organism resistance to the drugs (Azithromycin resistance C. trachomatis bacteria), or 
incomplete penetration of the drug at the site of infection (Adair 1998). 
 
6. Conclusion 
To conclude, Azithromycin can be considered as the most effective antibiotic to treat C. 
trachomatis infections in pregnancy. Azithromycin had a high success rate of eradicating the 
active infection, minimal gastrointestinal side effects encountered, and high levels of compliance 
from patients due to its unique pharmacokinetic profile. This antibiotic facilitates the fast and 
complete elimination of C. trachomatis infections in pregnancy with low recorded levels of 
recurrent infections attributed to its mode of action. More data regarding Azithromycin was 
accessible to this study compared to that of Clindamycin. Clindamycin, although very capable of 
eliminating C. trachomatis infections in pregnancy, there was a severe lack of data supporting 
these capabilities. Future research on more RCTs needs to be completed to determine the 
efficacy of Clindamycin. Moreover, Clindamycin could be considered as a second antibiotic to 
Azithromycin, in allergic circumstances of when antibiotic resistance of C. trachomatis to the 
azalide prevails. 
Table 03: Abbreviating each of the acronyms used in the text. 
sexually transmitted disease STD 
Pelvic Inflammatory Disease PID 
World Health Organisation WHO 
Randomised Control Trials RCTs 
Real-Time Polymerase Chain Reaction RT-PCR 
transfer Ribo Nucleic Acid  tRNA 
Ribosomal Ribo Nucleic Acid rRNA 
Messenger Ribo Nucleic Acid mRNA 
odds ratio OR 
confidence interval CI 
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